Protocol Page


	Study ID (Protocol Number)
	CA209-038


	STUDY LOCATIONS*
	Dana Farber Cancer Institute Boston, MA 02215 Recruiting	Dana Farber Cancer Institute Boston, MA 02215 Recruiting
	Dana Farber Cancer Institute Boston, MA 02215 Recruiting	Local Institution Chicago, IL 60612 Not yet recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
	STUDY OVERVIEW
	The purpose of this study is to evaluate pharmacodynamic changes of BMS-936558 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced).

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.